Health
The Economist: It’s not just obesity – drugs like Ozempic will change the world
As they become cheaper, they promise to improve billions of lives
GLP-1 receptor agonists are revolutionizing health care, moving beyond diabetes and obesity to treat cardiovascular, kidney, and possibly neurodegenerative diseases. As usage expands and costs drop, these drugs promise to enhance lives globally by reducing health risks associated with obesity and addiction.
Sign up for your early morning brew of the BizNews Insider to keep you up to speed with the content that matters. The newsletter will land in your inbox at 5:30am weekdays. Register here.
From The Economist, published under licence. The original article can be found on www.economist.com
© 2024 The Economist Newspaper Limited. All rights reserved.
The Economist
As they become cheaper, they promise to improve billions of lives
___STEADY_PAYWALL___